Effects of elbasvir and grazoprevir: A Synthesis of Findings from 29 Studies

  1. Home
  2. Effects of elbasvir and grazoprevir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of elbasvir and grazoprevir: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of elbasvir and grazoprevir: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major findings

Elbasvir and grazoprevir are a combination of NS5A and NS3/4A inhibitors. This combination has been shown to be effective in treating hepatitis C virus (HCV) genotypes 1 and 4 in various clinical trials and real-world experiences. 19 Elbasvir and grazoprevir have a high barrier to resistance-associated substitutions, which means that the virus is less likely to develop resistance to the drug. 19 The combination has demonstrated excellent efficacy and safety, especially in patients with compensated liver disease. 1 In Japan, elbasvir and grazoprevir are recommended as a first-line treatment for HCV genotype 1. 10 Elbasvir and grazoprevir have been shown to be effective for treating HCV in patients receiving hemodialysis. 26

Benefits and risks

Benefit summary

Elbasvir and grazoprevir have demonstrated a high sustained virological response rate (>95%) in various populations, including those with compensated liver disease. 19 1 The combination has a higher barrier to resistance-associated substitutions, making it a valuable option for treating HCV infection. 19 It has been found to be effective in treating both HCV genotype 1 and 4, and its safety and tolerability are appreciated in clinical treatment. 19 Elbasvir and grazoprevir are recommended as a first-line treatment for HCV genotype 1 in Japan. 10

Risk summary

Although elbasvir and grazoprevir have a good safety profile, some potential risks have been identified. The most common adverse effects include headache, fatigue, nasopharyngitis, nausea, and diarrhea. 23 In rare cases, low blood sugar (hypoglycemia) has been reported in patients receiving this treatment. 12 It is important to be aware of potential drug-drug interactions, especially with other medications used for HCV treatment. 18 6

Comparison between studies

Similarities between studies

Numerous studies consistently highlight the efficacy and tolerability of elbasvir and grazoprevir for treating chronic HCV infection. 19 1 25 9 13 11 These studies indicate the effectiveness of this combination in treating both HCV genotype 1 and 4. 19 1 14 4

Differences between studies

The studies differ in terms of the treatment duration, patient population, and evaluation criteria. For example, some studies utilize a 12-week treatment regimen, while others use 16 or 18 weeks. 23 Furthermore, some studies focus exclusively on patients with HCV genotype 1, whereas others include both genotypes 1 and 4. 19 2 The evaluation criteria also vary, with some studies focusing only on SVR12 (sustained virological response at 12 weeks after treatment completion) and others including additional assessments like HCV-related symptoms and functional well-being. 7 These variations in study methodology should be considered when interpreting the results.

Consistency and inconsistency of the results

Elbasvir and grazoprevir have been consistently shown to be effective and well-tolerated in treating HCV infection. 19 1 25 9 13 11 However, some studies have reported potential adverse effects, such as low blood sugar and liver or kidney issues. 12 1

Considerations for real-world application

Elbasvir and grazoprevir have shown promise in treating HCV infection, but it's essential to consult a healthcare provider before starting treatment. Patients should discuss their medical history and any current medications to ensure this combination is suitable for them. Additionally, potential drug-drug interactions should be discussed with the healthcare provider, especially with other medications used for HCV treatment. 18 6

Limitations of current research

The research on elbasvir and grazoprevir is primarily based on clinical trials and real-world studies, which are conducted under specific conditions and may not be fully generalizable to all individuals. Long-term effects of this combination remain under investigation. 18 6

Future research directions

Future research should focus on evaluating the long-term effects of elbasvir and grazoprevir, exploring drug-drug interactions, and determining its safety and efficacy in specific populations, including pregnant women and children. Further investigations are necessary to understand the effects of this combination in various clinical settings and to optimize treatment strategies. 3

Conclusion

Elbasvir and grazoprevir have demonstrated significant potential as an effective treatment option for HCV infection, with a favorable safety profile. 19 However, individual patients should always consult with their healthcare providers to determine if this combination is appropriate for them. 18 6 HCV is a treatable disease, and elbasvir and grazoprevir represent a promising tool in the fight against this viral infection. If you have concerns about HCV infection, consult a healthcare professional to discuss available treatment options.

Literature analysis of 29 papers
Positive Content
26
Neutral Content
0
Negative Content
3
Article Type
3
1
0
2
29
1.

Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.

Author: HsiehYi-Chung, LinChih-Lang, HungChao-Hung, ChenChien-Hung, TungShui-Yi, LinChun-Yen, HuTsung-Hui, LuSheng-Nan, ChienRong-Nan, SheenI-Shyan

HCV treatment efficacy
Liver adverse events
Renal adverse events

This study evaluated the real-world experience of elbasvir/grazoprevir in treating HCV genotype 1 patients with compensated liver disease. It found a sustained virologic response (SVR12) rate of 94.6% in the full analysis set and 99.1% in the per-protocol set. While liver and renal adverse events were infrequent, one patient developed autoimmune hepatitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.

Author: Gonzalez-PeraltaRegino P, WirthStefan, SquiresRobert H, MutschlerFrauke, LangThomas, PawlowskaMalgorzata, SluzewskiWojciech, Majda-StanislawskaEwa, FischlerBjorn, BalistreriWilliam F, JonasMaureen M, BlondetNiviann, RosenthalPhilip, AlkhouriNaim, RomeroRene, GrandhiAnjana, CastronuovoPatricia, CaroLuzelena, DuLihong, RosenbloomDaniel I S, HaberBarbara A

HCV Treatment

This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir that achieve similar plasma concentrations to those seen in adults, providing a foundation for optimized treatment in children with HCV.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.

Author: HillDeanna D, KramerJennifer R, ChaffinKassie R, MastT Christopher, RobertsonMichael N, KanwalFasiha, HaberBarbara A

Improved SVR rates
Lower SVR rates

Clinical trials revealed that elbasvir/grazoprevir treatment for 12 weeks led to lower sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) genotype 1a infection and baseline resistance-associated substitutions (RASs). Extending treatment duration to 16 weeks and adding ribavirin improved SVR rates in these patients.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.

Author: NguyenlaXammy, WehriEddie, Van DisErik, BieringScott B, YamashiroLivia H, ZhuChi, StroumzaJulien, Dugast-DarzacqClaire, GrahamThomas G W, WangXuanting, JockuschSteffen, TaoChuanjuan, ChienMinchen, XieWei, PatelDinshaw J, MeyerCindy, GarziaAitor, TuschlThomas, RussoJames J, JuJingyue, NäärAnders M, StanleySarah, SchaletzkyJulia

COVID-19 treatment

HCV NS5A inhibitors, like velpatasvir and elbasvir, synergistically enhance the antiviral efficacy of remdesivir against SARS-CoV-2, providing a promising strategy for treating COVID-19.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

6.

Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.

Author: HuiVicki Wing-Ki, AuChristopher Langjun, LamAmy Shuk Man, YipTerry Cheuk-Fung, TseYee-Kit, LaiJimmy Che-To, ChanHenry Lik-Yuen, WongVincent Wai-Sun, WongGrace Lai-Hung

Drug-drug interactions

This study examines the prevalence and degree of drug-drug interactions (DDIs) between direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) and other co-medications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.

Author: EvonDonna M, DongMeichen, ReeveBryce B, PeterJoy, MichaelLarry, LokAnna S, NelsonDavid R, StewartPaul W

Durable Improvement
Improved Symptoms

This study compared two antiviral drugs, ledipasvir/sofosbuvir and elbasvir/grazoprevir, for the treatment of chronic hepatitis C virus (HCV) infection. Both drugs were effective in improving symptoms and functional well-being, with no significant difference between the two.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.

Author: LiWencong, LiangJing, AnJihong, LiuLingdi, HouYihui, LiLu, ZhaoWen, CuiLuyao, XueNingning, Al-DhaminZaid, HanTao, NanYuemin, ZhangLiaoyun

Effective Treatment
High SVR
None

This study analyzed the prevalence of HCV genotypes and the efficacy and safety of direct-acting antiviral (DAA) treatment for HCV-infected patients in North and Northeast China. Genotypes 1b and 2a were most prevalent. DAA regimens including elbasvir/grazoprevir, sofosbuvir/velpatasvir, and sofosbuvir/ledipasvir achieved high sustained virological response (SVR) rates (99.01% for SVR12 and 98.43% for SVR24).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

9.

Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?

Author: CzarneckaPaulina, CzarneckaKinga, TroninaOlga, BaczkowskaTeresa, DurlikMagdalena

Kidney transplantation
Organ availability
Organ rejection

This review examines the use of HCV NAT+ donor organs for transplantation, highlighting the effectiveness and safety of this approach but emphasizing the need for long-term data on the consequences.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Video-Audio MediaMedia that combines video and audio. Includes movies, TV shows, and online videos.

Language : English

10.

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.

Author: KayaMichihiro, NakamuraKazuyo, SugiyamaKyohei, KinaeAyumi, YamaguchiHiromi, UkitaHirotoshi, OdagiriKeiichi, UjiieChika, KatoJun, KageyamaFujito, NaguraMariko, MatsushitaKumi, SugiueKaori, IshidaHiroki, EndoShinya, SuzukiTakaya

Hepatitis C treatment

This retrospective multicenter study compared the effectiveness and safety of three direct-acting antiviral (DAA) regimens - ledipasvir/sofosbuvir, elbasvir/grazoprevir, and glecaprevir/pibrentasvir - in real-world clinical practice for patients with untreated hepatitis C virus genotype 1 in Japan.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

11.

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.

Author: KramerJennifer R, PuenpatomAmy, CaoYumei, YuXian, El-SeragHashem B, KanwalFasiha

EBR/GZR efficacy
HCV cure rate

Elbasvir/grazoprevir (EBR/GZR) has demonstrated high rates of virologic cure in patients with HCV genotype 1 infection, including those with opioid use disorder and multiple comorbidities. This real-world study highlights the effectiveness of EBR/GZR in this complex patient population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.

Author: JiQinghua, ChuXudong, ZhouYugui, LiuXuan, ZhaoWei, YeWei

Sustained virologic response
Fatigue
Headache
Nausea

Grazoprevir/elbasvir (GZR/EBR) treatment showed high efficacy and safety in hemodialysis-dependent patients with genotype 1b acute hepatitis C (AHC). All 68 patients achieved sustained virologic response at 12 weeks after treatment cessation. The most common adverse events were fatigue, headache, and nausea.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.

Author: CalvarusoVincenza, PettaSalvatore, FerraroDonatella, La MantiaClaudia, GibilaroGerlando, ReinaGiada, Di MaioVelia Chiara, LicataAnna, Ceccherini-SilbersteinFrancesca, Di MarcoVito, CraxìAntonio

High SVR rate
Short treatment duration
Relapse

A short 8-week course of elbasvir/grazoprevir was highly effective in achieving sustained viral response (SVR) in treatment-naive patients with genotype-1b Hepatitis C virus (HCV) infection and mild to moderate liver fibrosis, with an SVR12 rate of 97.3%.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

Author: SulkowskiMark S, MoonJuhi S, ShermanKenneth E, MorelliGiuseppe, DarlingJama M, MuirAndrew J, KhaliliMandana, FishbeinDawn A, HinestrosaFederico, ShiffmanMitchell L, Di BisceglieAdrian, Rajender ReddyK, PearlmanBrian, LokAnna S, FriedMichael W, StewartPaul W, PeterJoy, WadsworthSummer, KixmillerScott, SloanAnquenette, VainoriusMonika, HornePatrick M, MichaelLarry, DongMeichen, EvonDonna M, SegalJodi B, NelsonDavid R,

HCV treatment
Viral response
Adverse events

Ledipasvir/sofosbuvir and elbasvir/grazoprevir were equally effective in treating HCV genotype 1, with high sustained viral response rates and few adverse effects. Both regimens are supported by current guidelines.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.

Author: MacíasJuan, TéllezFrancisco, de Los SantosIgnacio, MoranoLuis E, MerinoDolores, GranadosRafael, Vera-MendezFrancisco, González-SernaAlejandro, Campo-MoneoEsther, García-FraileLucio, GarcíaFederico, RealLuis M, PinedaJuan A,

HCV treatment

Elbasvir/grazoprevir (EBR/GZR) achieved high sustained virological response (SVR) rates in people who inject drugs (PWID) with and without opioid agonist therapy (OAT) in real-world conditions. However, recent drug users had lower SVR rates.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection.

Author: ChuaypenNatthaya, JinatoThananya, AvihingsanonAnchalee, ChirapongsathornSakkarin, CheevadhanarakSupapon, NookaewIntawat, TanakaYasuhito, TangkijvanichPisit

Microbial restoration
Viral eradication

This study found that direct-acting antivirals (DAAs) used to treat hepatitis C virus (HCV) infection had a short-term effect on restoring microbial dysbiosis in the gut. The gut microbiota of HCV-infected patients, both with and without HIV coinfection, was less diverse and distinct from healthy controls before treatment. However, after successful treatment, responders experienced improvement in microbial dysbiosis, especially those with low fibrosis. This suggests that DAA treatment may contribute to reducing HCV-related complications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy.

Author: KuoMeng Hsuan, TsengChih-Wei, LeeChi-Hui, YangYa-Ching, WuHsin-Ju, LinHsiu-Ju, ChuYa-Lan, ChenYen-Chun, TsengKuo-Chih

Cost avoidance
Adverse drug events

This prospective observational study investigated the impact of pharmaceutical care programs for the management of contraindicated drug-drug interactions (DDIs) in direct-acting antivirals (DAAs) therapy in 1053 patients. The study found that pharmaceutical care programs effectively identified and managed contraindicated DDIs, leading to a high acceptance rate of pharmacists' recommendations and substantial cost avoidance of preventable adverse drug events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

19.

Elbasvir and grazoprevir for the treatment of hepatitis C.

Author: WangSzu-Jen, HuangChung-Feng, YuMing-Lung

Treats HCV

Elbasvir/Grazoprevir (EBR/GZR) is a combination of NS5A and NS3/4A inhibitors that is effective in the treatment of hepatitis C virus (HCV) genotypes 1 and 4. EBR/GZR has a higher barrier to resistance-associated substitutions and is well tolerated in clinical treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.

Author: Laguno CentenoMontserrat, AlvarezBeatriz, Martínez-RebollarMaria, de la MoraLorena, PrietoLaura, de LazzariElisa, González-CordónAna, TorresBerta, CabelloAlfonso, GorgolasMiguel, MallolasJosep

AHC treatment

This study highlights the growing prevalence of acute hepatitis C virus (AHC) infection among HIV+ men who have sex with men (MSM). Prior to the advent of effective Direct-Acting-Antivirals (DAAs), the recommended treatment for AHC was pegylated-interferon plus ribavirin, which was often rejected due to its side effects. This study underscores the importance of accessible and effective treatment options for AHC in this population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

23.

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.

Author: NangiaGayatri, VierlingJohn M, KwoPaul, BrownDeborah D, KlopferStephanie O, RobertsonMichael N, HaberBarbara A, ReddyK Rajender

HCV treatment
Safe for CKD
Safe for IBLD
Safe for OAT
ALT elevation
Diarrhea
Fatigue
Headache
Nasopharyngitis
Nausea

Elbasvir/grazoprevir is a safe treatment option for individuals with chronic hepatitis C virus (HCV) infection. It is effective for genotypes 1 and 4, even in individuals with challenging comorbidities like chronic kidney disease or inherited blood disorders. While the drug is generally safe, some side effects may occur at higher frequencies when combined with ribavirin.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.

Author: PijnenburgDaniëlle W M, van SeyenMinou, AbbinkEvertine J, ColbersAngela, DrenthJoost P H, BurgerDavid M

Drug resistance
Drug toxicity
Treatment failure

Crushing elbasvir/grazoprevir tablets is not recommended due to the lack of information about adequate absorption after crushing and potential for treatment failure, resistance development, or toxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

26.

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.

Author: LiuChen-Hua, PengCheng-Yuan, FangYu-Jen, KaoWei-Yu, YangSheng-Shun, LinCheng-Kuan, LaiHsueh-Chou, SuWen-Pang, FangSheng-Uei, ChangChun-Chao, SuTung-Hung, LiuChun-Jen, ChenPei-Jer, ChenDing-Shinn, KaoJia-Horng

HCV GT1b cure
Well-tolerated
ALT elevation
Hemoglobin decrease
Myocardial infarction
Suicide

Elbasvir/grazoprevir (EBR/GZR) is effective and well-tolerated for East-Asian hepatitis C virus genotype 1b patients receiving hemodialysis. This prospective study found a sustained virologic response rate of 95% by intention-to-treat analysis and 100% by modified intention-to-treat analysis. While some patients experienced adverse events, none were considered related to EBR/GZR.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

28.

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.

Author: ChengPin-Nan, ChenChi-Yi, YuMing-Lung, LinChun-Che, LinChun-Yen, PengCheng-Yuan, TsengKuo-Chih, LoChing-Chu, TsengI-Hao, LiuChun-Jen

Effective treatment
Well tolerated

Elbasvir/grazoprevir (EBR/GZR) treatment was highly effective and well tolerated in Taiwanese patients with HCV genotype 1. The sustained virological response at week 12 (SVR12) rate was 99.5% (1169/1175).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

29.

Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.

Author: AsselahTarik, ZeuzemStefan, ReauNancy, HwangPeggy, LongJianmin, TalwaniRohit, RobertsonMichael N, HaberBarbara A

Hepatitis C Treatment
Adverse Events

Elbasvir/grazoprevir for 12 weeks was safe and highly effective in participants aged ≤35 years with hepatitis C virus genotype 1 or 4 infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.